About JDS Pharmaceuticals
JDS Pharmaceuticals is a company based in New York (United States) founded in 2004 was acquired by Noven in July 2007. JDS Pharmaceuticals has raised $62 million across 1 funding round from investors including AIG, Noven and Galen Partners. JDS Pharmaceuticals operates in a competitive market with competitors including Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
- Headquarter New York, United States
- SectorsHealthcare
- Website jdspharma.com
- Acquired by Noven (Jul 2007)
Funding Insights of JDS Pharmaceuticals
JDS Pharmaceuticals has successfully raised a total of $62M through 1 strategic funding round. The most recent funding activity was a Series A round of $62 million completed in August 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62M
- Total Rounds 1
- Last Round Series A — $62M
- First Round $62M
(Aug 2004)
- Investors Count 2
All 1 funding rounds of JDS Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2004 | $62M | Series A | – | AIG, Galen Partners | – |
3 investors in total: 3 institutional.
Investors in JDS Pharmaceuticals
JDS Pharmaceuticals has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include AIG, Noven and Galen Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in the US | – | galen.com | Stamford, United States | |
AIG is recognized as a leading global insurance organization. | 1919 | aig.com | New York, United States | |
A specialty pharmaceutical company focused on transdermal drug delivery. | 1987 | noven.com | Miami, United States |
Investor details for JDS Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of JDS Pharmaceuticals
3 dated milestones of JDS Pharmaceuticals across 3 years, from founding to its latest funding, stage changes and deals.
- Founded JDS Pharmaceuticals is founded.
- Funding First funding round of $62.0M.
- Exit Acquired by Noven.
Competitors of JDS Pharmaceuticals
JDS Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alto Neuroscience, Newron Pharmaceuticals, Supernus Pharmaceuticals, Neurovance and Seaport Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| altoneuroscience.com | 2019 | San Francisco, United States | $144.72M | 34 | AI-driven drug discovery platform for neurological diseases based on patients biomarkers | |
| newron.com | 1999 | Milan, Italy | $54.94M | – | Therapies for central nervous system diseases and pain are developed. | |
| supernus.com | 2005 | Rockville, United States | – | 652 | Specialty pharmaceutical products for CNS diseases are developed and commercialized. | |
| neurovance.com | 2011 | Cambridge, United States | $53.03M | 7 | Neurochemical modulators for ADHD treatment are developed by Neurovance. | |
| seaporttx.com | 2020 | Boston, United States | $325M | – | Novel therapeutics for neuropsychiatric disorders are developed using proprietary technology. | |
| pasithea.com | 2020 | Miami Beach, United States | $1.46M | 15 | Pasithea is focused on developing treatments for neurological disorders. | |
| synchroneuron.com | 2006 | Newton, United States | $26M | – | Improved acamprosate formulations are developed for neuropsychiatric disorders. | |
| naurex.com | 2008 | Evanston, United States | $162.11M | – | Novel therapies for depression and CNS disorders are developed clinically. | |
| cadenttx.com | 2010 | Cambridge, United States | $63.73M | 13 | Precision medicines for neurological diseases are developed by Cadent Therapeutics. | |
| reunionneuro.com | 2022 | Toronto, Canada | $103M | – | Therapeutics for mental health conditions are developed using serotonergic psychedelics. |
Detailed competitors of JDS Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Jds Pharmaceuticals
Complete news archive for JDS Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to JDS Pharmaceuticals
10 companies that operate in the same segment as JDS Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about JDS Pharmaceuticals
JDS Pharmaceuticals was founded in 2004.
JDS Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
JDS Pharmaceuticals is a funded company, having raised a total of $62M across 1 funding round to date. The company's 1st funding round was a Series A of $62M, raised on Aug 2004.
JDS Pharmaceuticals was established in 2004 in New York, United States, as a specialty pharmacy focused on small molecule drugs for psychiatry and womens health. Two products, Lithobid for bipolar disorder and Pexeva for panic disorder, were marketed in the US. Four additional drugs were under development for bipolar disorder, migraines, epilepsy, and vasomotor symptoms. The company was acquired by Noven in July 2007 for 125 million.
JDS Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Newron Pharmaceuticals.
JDS Pharmaceuticals has 3 investors. Key investors include AIG, Noven, and Galen Partners.
Yes. JDS Pharmaceuticals was acquired by Noven in July 2007.